The BioPharm Brief: Bispecifics, Biocatalysis, and Dual-Pathway Therapies

May 08, 10:17 PM
Headliner
Share
Subscribe

Today’s BioPharm Brief covers next-generation immunotherapy, scalable peptide manufacturing, and Johnson & Johnson’s dual-pathway approach to inflammatory bowel disease treatment.

Share
Subscribe
Next
The BioPharm Brief: Bispecifics, Biocatalysis, and Dual-Pathway Therapies
Top episodes
The BioPharm Brief: Early Design Risks, Oncology Signals, and a Biosimilars Power Move
by The BioPharm Brief
The BioPharm Brief: What’s the Big Deal About Multispecific T-Cell Engagers in Cancer and Autoimmune Diseases?
by The BioPharm Brief
The BioPharm Brief: Regulatory Shifts, Rare Disease Innovation, and Precision Drug Development Trends
by The BioPharm Brief